Preventive strategies targeting cytokine modulation, such as IL-1β antagonists, merit investigation given their proven efficacy in post-pancreatitis diabetes prevention.[24,25] While current evidence remains circumstantial, several key research priorities have emerged. This evidence concerns the gene IL1B and diabetes mellitus.